{
    "PMC8668943_3": [
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "1 copy",
                "reference group": "2 copies",
                "analysis type": "univariate",
                "odds ratio": "0.29",
                "confidence interval": "0.12-0.71",
                "P-value": "0.007",
                "Bonferroni corrected P-value": "0.112"
            },
            "measures": "[odds ratio, confidence interval, P-value, Bonferroni corrected P-value]",
            "outcomes": "[0.29, 0.12-0.71, 0.007, 0.112]"
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "1 copy",
                "reference group": "2 copies",
                "analysis type": "adjusted",
                "adjusted odds ratio": "0.37",
                "confidence interval": "0.15-0.90",
                "P-value": "0.029",
                "Bonferroni corrected P-value": "0.464"
            },
            "measures": "[adjusted odds ratio, confidence interval, P-value, Bonferroni corrected P-value]",
            "outcomes": "[0.37, 0.15-0.90, 0.029, 0.464]"
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "2 copies",
                "reference group": "self",
                "analysis type": "univariate",
                "odds ratio": "Ref",
                "P-value": "N/A",
                "Bonferroni corrected P-value": "N/A"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "2 copies",
                "reference group": "self",
                "analysis type": "adjusted",
                "adjusted odds ratio": "Ref",
                "P-value": "N/A",
                "Bonferroni corrected P-value": "N/A"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "\u22653 copies",
                "reference group": "2 copies",
                "analysis type": "univariate",
                "odds ratio": "0.99",
                "confidence interval": "0.63-1.57",
                "P-value": "0.978",
                "Bonferroni corrected P-value": "N/A"
            },
            "measures": "[odds ratio, confidence interval, P-value]",
            "outcomes": "[0.99, 0.63-1.57, 0.978]"
        },
        {
            "subject": {
                "gene": "FCGR2C",
                "gene copy number": "\u22653 copies",
                "reference group": "2 copies",
                "analysis type": "adjusted",
                "adjusted odds ratio": "0.74",
                "confidence interval": "0.43-1.27",
                "P-value": "0.275",
                "Bonferroni corrected P-value": "N/A"
            },
            "measures": "[adjusted odds ratio, confidence interval, P-value]",
            "outcomes": "[0.74, 0.43-1.27, 0.275]"
        }
    ],
    "PMC5817808_2": [
        {
            "subject": {
                "study_population_mortality_rate": "2.58%",
                "feeding_option": "ERF",
                "feeding_option_mortality_rate": "2.41%",
                "mortality_rate_comparison_to_EBF": "5.5 folds lower",
                "mortality_rate_comparison_to_MF": "5.5 folds lower"
            },
            "measures": "[p]",
            "outcomes": "[0.032]"
        },
        {
            "subject": {
                "study_population_mortality_rate": "2.58%",
                "feeding_option": "EBF",
                "feeding_option_mortality_rate": "2.45%",
                "mortality_rate_comparison_to_ERF": "5.4 folds lower",
                "mortality_rate_comparison_to_MF": "5.4 folds lower"
            },
            "measures": "[p]",
            "outcomes": "[0.032]"
        },
        {
            "subject": {
                "study_population_mortality_rate": "2.58%",
                "feeding_option": "MF",
                "feeding_option_mortality_rate": "13.33%",
                "mortality_rate_comparison_to_EBF": "5.4 folds higher",
                "mortality_rate_comparison_to_ERF": "5.5 folds higher"
            },
            "measures": "[p]",
            "outcomes": "[0.032]"
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "feeding_option": "Exclusive breast feeding",
                "unadjusted_HR": "1.35 [0.52-3.49]",
                "adjusted_HR": "1.16 [0.44-3.08]"
            },
            "measures": "[0.52-3.49]",
            "outcomes": [
                "[0.44-3.08]",
                "[p_unadjusted, p_adjusted]",
                "[0.54, 0.76]"
            ]
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "feeding_option": "Mixed feeding",
                "unadjusted_HR": "0.31 [0.04-2.42]",
                "adjusted_HR": "0.44 [0.053-3.74]"
            },
            "measures": "[0.04-2.42]",
            "outcomes": [
                "[0.053-3.74]",
                "[p_unadjusted, p_adjusted]",
                "[0.26, 0.45]"
            ]
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "feeding_option": "Exclusive replacement feeding",
                "unadjusted_HR": "Ref",
                "adjusted_HR": "Ref"
            },
            "measures": "[p_unadjusted, p_adjusted]",
            "outcomes": "[Ref, Ref]"
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "HIV_status": "Positive",
                "unadjusted_HR": "0.31 [0.11-0.90]",
                "adjusted_HR": "0.30 [0.08-1.11]"
            },
            "measures": "[0.11-0.90]",
            "outcomes": [
                "[0.08-1.11]",
                "[p_unadjusted, p_adjusted]",
                "[0.032, 0.071]"
            ]
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "HIV_status": "Negative",
                "unadjusted_HR": "Ref",
                "adjusted_HR": "Ref"
            },
            "measures": "[p_unadjusted, p_adjusted]",
            "outcomes": "[Ref, Ref]"
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "birth_weight": ">=2500 g",
                "unadjusted_HR": "0.88 [0.34-2.28]",
                "adjusted_HR": "0.93 [0.21-4.12]"
            },
            "measures": "[0.34-2.28]",
            "outcomes": [
                "[0.21-4.12]",
                "[p_unadjusted, p_adjusted]",
                "[0.80, 0.92]"
            ]
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "birth_weight": "<2500 g",
                "unadjusted_HR": "Ref",
                "adjusted_HR": "Ref"
            },
            "measures": "[p_unadjusted, p_adjusted]",
            "outcomes": "[Ref, Ref]"
        },
        {
            "subject": {
                "context": "HIV exposed infants",
                "study_location": "Essos hospital center",
                "program": "PMTCT",
                "age": "24 months",
                "test": "Global Schoenfeld residuals test"
            },
            "measures": "[p]",
            "outcomes": "[0.23]"
        }
    ],
    "PMC5574138_3": [
        {
            "subject": {
                "covariate": "Length of follow-up",
                "estimate": "-0.0138",
                "standard error": "0.0666",
                "confidence interval": "(-0.1322\u20130.1046)",
                "analysis type": "meta-regression",
                "dependent variable": "study",
                "independent variables": "covariates",
                "context": "regression model",
                "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[estimate, standard error, confidence interval]",
            "outcomes": "[-0.0138, 0.0666, (-0.1322\u20130.1046)]"
        },
        {
            "subject": {
                "covariate": "Median CD4 count",
                "estimate": "-0.0034",
                "standard error": "0.0066",
                "confidence interval": "(-0.0150\u20130.0079)",
                "analysis type": "meta-regression",
                "dependent variable": "study",
                "independent variables": "covariates",
                "context": "regression model",
                "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[estimate, standard error, confidence interval]",
            "outcomes": "[-0.0034, 0.0066, (-0.0150\u20130.0079)]"
        },
        {
            "subject": {
                "covariate": "Median age",
                "estimate": "0.0415",
                "standard error": "0.0503",
                "confidence interval": "(-0.1013\u20130.0755)",
                "analysis type": "meta-regression",
                "dependent variable": "study",
                "independent variables": "covariates",
                "context": "regression model",
                "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[estimate, standard error, confidence interval]",
            "outcomes": "[0.0415, 0.0503, (-0.1013\u20130.0755)]"
        },
        {
            "subject": {
                "covariate": "Year of publication",
                "estimate": "0.0637",
                "standard error": "0.0815",
                "confidence interval": "(-0.1736\u20130.0980)",
                "analysis type": "meta-regression",
                "dependent variable": "study",
                "independent variables": "covariates",
                "context": "regression model",
                "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[estimate, standard error, confidence interval]",
            "outcomes": "[0.0637, 0.0815, (-0.1736\u20130.0980)]"
        },
        {
            "subject": {
                "covariate": "Female proportion",
                "estimate": "-0.5305",
                "standard error": "1.4575",
                "confidence interval": "(-3.6792\u20132.6183)",
                "analysis type": "meta-regression",
                "dependent variable": "study",
                "independent variables": "covariates",
                "context": "regression model",
                "additional covariates": "length of follow-up, median CD4 cell counts, median age, year of publication, proportion of female"
            },
            "measures": "[estimate, standard error, confidence interval]",
            "outcomes": "[-0.5305, 1.4575, (-3.6792\u20132.6183)]"
        }
    ],
    "PMC4794224_2": [
        {
            "subject": {
                "KIR Genotypes": "KIR2DL1",
                "Frequency": "97%",
                "N": "966"
            },
            "measures": "[Frequency]",
            "outcomes": "[97%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DL3",
                "Frequency": "72%",
                "N": "719"
            },
            "measures": "[Frequency]",
            "outcomes": "[72%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DL4",
                "Frequency": "100%",
                "N": "993"
            },
            "measures": "[Frequency]",
            "outcomes": "[100%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DL5",
                "Frequency": "55%",
                "N": "547"
            },
            "measures": "[Frequency]",
            "outcomes": "[55%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DL2*004",
                "Frequency": "3%",
                "N": "31"
            },
            "measures": "[Frequency]",
            "outcomes": "[3%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DL2*001/2/3/5",
                "Frequency": "55%",
                "N": "544"
            },
            "measures": "[Frequency]",
            "outcomes": "[55%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DP1",
                "Frequency": "97%",
                "N": "964"
            },
            "measures": "[Frequency]",
            "outcomes": "[97%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DS1",
                "Frequency": "55%",
                "N": "548"
            },
            "measures": "[Frequency]",
            "outcomes": "[55%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DS2",
                "Frequency": "59%",
                "N": "581"
            },
            "measures": "[Frequency]",
            "outcomes": "[59%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DS3",
                "Frequency": "40%",
                "N": "401"
            },
            "measures": "[Frequency]",
            "outcomes": "[40%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DS4",
                "Frequency": "100%",
                "N": "993"
            },
            "measures": "[Frequency]",
            "outcomes": "[100%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR2DS5",
                "Frequency": "28%",
                "N": "281"
            },
            "measures": "[Frequency]",
            "outcomes": "[28%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR3DL1",
                "Frequency": "94%",
                "N": "929"
            },
            "measures": "[Frequency]",
            "outcomes": "[94%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR3DL2",
                "Frequency": "100%",
                "N": "993"
            },
            "measures": "[Frequency]",
            "outcomes": "[100%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR3DL3",
                "Frequency": "100%",
                "N": "993"
            },
            "measures": "[Frequency]",
            "outcomes": "[100%]"
        },
        {
            "subject": {
                "KIR Genotypes": "KIR3DS1",
                "Frequency": "36%",
                "N": "354"
            },
            "measures": "[Frequency]",
            "outcomes": "[36%]"
        },
        {
            "subject": {
                "Context": "Studied cohort",
                "Source": "Tables 2, 3 and 4"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        },
        {
            "subject": {
                "Caption": "Frequency of KIR alleles"
            },
            "measures": "[ ]",
            "outcomes": "[ ]"
        }
    ],
    "PMC9077443_2": [
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "events per total PY in cabotegravir group": "4/1956 (0.20%)",
                "events per total PY in TDF-FTC group": "36/1942 (1.85%)",
                "HR (95% CI)": "0.12 (0.05\u20130.31)",
                "p value": "<0.0001"
            },
            "measures": "[HR]",
            "outcomes": "[0.12]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "age group": "<25 years",
                "events per total PY in cabotegravir group": "3/866 (0.35%)",
                "events per total PY in TDF-FTC group": "20/851 (2.34%)",
                "HR (95% CI)": "0.17 (0.05\u20130.54)"
            },
            "measures": "[HR]",
            "outcomes": "[0.17]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "age group": "\u226525 years",
                "events per total PY in cabotegravir group": "1/1090 (0.09%)",
                "events per total PY in TDF-FTC group": "16/1091 (1.47%)",
                "HR (95% CI)": "0.09 (0.02\u20130.49)"
            },
            "measures": "[HR]",
            "outcomes": "[0.09]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "contraceptive method": "DMPA",
                "events per total PY in cabotegravir group": "3/1009 (0.30%)",
                "events per total PY in TDF-FTC group": "21/1000 (2.10%)",
                "HR (95% CI)": "0.16 (0.05\u20130.53)"
            },
            "measures": "[HR]",
            "outcomes": "[0.16]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "contraceptive method": "NET-EN",
                "events per total PY in cabotegravir group": "1/175 (0.57%)",
                "events per total PY in TDF-FTC group": "6/182 (3.30%)",
                "HR (95% CI)": "0.22 (0.03\u20131.48)"
            },
            "measures": "[HR]",
            "outcomes": "[0.22]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "contraceptive method": "Implant",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "8/607 (1.32%)",
                "HR (95% CI)": "0.06 (0.00\u20131.16)"
            },
            "measures": "[HR]",
            "outcomes": "[0.06]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "contraceptive method": "Other",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "1/152 (0.66%)",
                "HR (95% CI)": "0.32 (0.01\u20139.89)"
            },
            "measures": "[HR]",
            "outcomes": "[0.32]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "BMI group": "\u226430 kg/m\u00b2",
                "events per total PY in cabotegravir group": "4/1389 (0.29%)",
                "events per total PY in TDF-FTC group": "27/1447 (1.87%)",
                "HR (95% CI)": "0.16 (0.06\u20130.45)",
                "p value": "0.47"
            },
            "measures": "[HR]",
            "outcomes": "[0.16]"
        },
        {
            "subject": {
                "caption": "Cabotegravir effectiveness, overall and by subgroup",
                "analysis": "ITT",
                "endpoint": "primary",
                "group": "TDF-FTC",
                "BMI group": ">30 kg/m\u00b2",
                "events per total PY in cabotegravir group": "0",
                "events per total PY in TDF-FTC group": "9/495 (1.82%)",
                "HR (95% CI)": "0.05 (0.00\u20130.96)"
            },
            "measures": "[HR]",
            "outcomes": "[0.05]"
        },
        {
            "subject": {
                "footnote": "median unbiased estimate HR (95% CI) for cabotegravir versus TDF-FTC overall displayed"
            }
        }
    ],
    "PMC10294491_2": [
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis type": "original analysis on rate ratio scale",
                "group": "TDF/FTC",
                "no. subjects": "2693",
                "PYFU": "4386",
                "incident HIV infections": "11",
                "incidence rate (per 100 PYFU)": "0.251",
                "rate ratio (95% CI)": "REF"
            },
            "measures": "[PYFU, incident HIV infections, incidence rate (per 100 PYFU)]",
            "outcomes": "[4386, 11, 0.251]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis type": "original analysis on rate ratio scale",
                "group": "TAF/FTC",
                "no. subjects": "2694",
                "PYFU": "4370",
                "incident HIV infections": "6",
                "incidence rate (per 100 PYFU)": "0.137",
                "rate ratio (95% CI)": "0.55 (0.20, 1.48)"
            },
            "measures": "[PYFU, incident HIV infections, incidence rate (per 100 PYFU)]",
            "outcomes": "[4370, 6, 0.137]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis type": "re-analysis using an averted infections framework",
                "group": "TDF/FTC",
                "PYFU": "4386",
                "observed infections": "11",
                "predicted infections": "90.4",
                "averted infections": "79.4",
                "averted infections ratio (95% CI)": "REF"
            },
            "measures": "[PYFU, observed infections, predicted infections, averted infections]",
            "outcomes": "[4386, 11, 90.4, 79.4]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "analysis type": "re-analysis using an averted infections framework",
                "group": "TAF/FTC",
                "PYFU": "4370",
                "observed infections": "6",
                "predicted infections": "90.0",
                "averted infections": "84.0",
                "averted infections ratio (95% CI)": "1.06 (0.96\u20131.17)"
            },
            "measures": "[PYFU, observed infections, predicted infections, averted infections]",
            "outcomes": "[4370, 6, 90.0, 84.0]"
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "footnote context": "applying counterfactual placebo incidence rate of 2.06 per 100 PYFU (lower 2.5% credibility limit)"
            },
            "measures": "[]",
            "outcomes": ""
        },
        {
            "subject": {
                "trial": "DISCOVER",
                "citation context": "6 incident HIV infections in TAF-FTC arm"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC6158807_3": [
        {
            "subject": {
                "event_type": "Composite endpoint",
                "total_events": "692",
                "no_of_event": "123",
                "person_year_follow_up": "4071",
                "rate_per_100_person_year": "3.02",
                "rate_95_CI": "(2.53\u20133.61)"
            },
            "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
            "outcomes": "[123, 4071, 3.02]"
        },
        {
            "subject": {
                "event_type": "Composite endpoint",
                "total_events": "692",
                "current_CD4_CD8_ratio": "< 0.3",
                "no_of_event": "21",
                "person_year_follow_up": "184",
                "rate_per_100_person_year": "11.42",
                "rate_95_CI": "(7.45\u201317.52)",
                "p_value": "< 0.001"
            },
            "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
            "outcomes": "[21, 184, 11.42]"
        },
        {
            "subject": {
                "event_type": "Composite endpoint",
                "total_events": "692",
                "current_CD4_CD8_ratio": "0.30\u20130.45",
                "no_of_event": "28",
                "person_year_follow_up": "496",
                "rate_per_100_person_year": "5.64",
                "rate_95_CI": "(3.90\u20138.17)",
                "p_value": "< 0.001"
            },
            "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
            "outcomes": "[28, 496, 5.64]"
        },
        {
            "subject": {
                "event_type": "Composite endpoint",
                "total_events": "692",
                "current_CD4_CD8_ratio": "> 0.45",
                "no_of_event": "72",
                "person_year_follow_up": "3227",
                "rate_per_100_person_year": "2.23",
                "rate_95_CI": "(1.77\u20132.81)",
                "p_value": "< 0.001"
            },
            "measures": "[no_of_event, person_year_follow_up, rate_per_100_person_year]",
            "outcomes": "[72, 3227, 2.23]"
        }
    ],
    "PMC7522205_2": [
        {
            "subject": {
                "HIV-1 Genotype": "Total",
                "Patients": "no. (%), 2845 (100.0)",
                "CD4+ median (IQR)": "160 (49\u2013310)",
                "Study Population": "Newly diagnosed HIV patients",
                "Context": "Baseline CD4+ cell counts",
                "Source": "Table 2",
                "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            }
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF01_AE",
                "Patients": "no. (%), 1687 (59.3)",
                "CD4+ median (IQR)": "111 (31\u2013279)",
                "Unadjusted Coefficient": "0",
                "Adjusted Coefficient": "0",
                "Study Population": "Newly diagnosed HIV patients",
                "Context": "Baseline CD4+ cell counts",
                "Source": "Table 2",
                "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            }
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF07_BC",
                "Patients": "no. (%), 254 (8.9)",
                "CD4+ median (IQR)": "250 (156\u2013377)",
                "Unadjusted Coefficient": "139",
                "Unadjusted 95% CI": "(117\u2013161)",
                "Unadjusted P": "<0.001",
                "Adjusted Coefficient": "113",
                "Adjusted 95% CI": "(86\u2013140)",
                "Adjusted P": "<0.001",
                "Study Population": "Newly diagnosed HIV patients",
                "Context": "Baseline CD4+ cell counts",
                "Source": "Table 2",
                "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
            "outcomes": "[139, (117\u2013161), <0.001, 113, (86\u2013140), <0.001]"
        },
        {
            "subject": {
                "HIV-1 Genotype": "CRF08_BC",
                "Patients": "no. (%), 728 (25.6)",
                "CD4+ median (IQR)": "205 (108\u2013327)",
                "Unadjusted Coefficient": "94",
                "Unadjusted 95% CI": "(73\u2013115)",
                "Unadjusted P": "<0.001",
                "Adjusted Coefficient": "80",
                "Adjusted 95% CI": "(65\u201395)",
                "Adjusted P": "<0.001",
                "Study Population": "Newly diagnosed HIV patients",
                "Context": "Baseline CD4+ cell counts",
                "Source": "Table 2",
                "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
            "outcomes": "[94, (73\u2013115), <0.001, 80, (65\u201395), <0.001]"
        },
        {
            "subject": {
                "HIV-1 Genotype": "Others",
                "Patients": "no. (%), 176 (6.2)",
                "CD4+ median (IQR)": "198 (89\u2013355)",
                "Unadjusted Coefficient": "87",
                "Unadjusted 95% CI": "(46\u2013128)",
                "Unadjusted P": "<0.001",
                "Adjusted Coefficient": "72",
                "Adjusted 95% CI": "(37\u2013107)",
                "Adjusted P": "<0.001",
                "Study Population": "Newly diagnosed HIV patients",
                "Context": "Baseline CD4+ cell counts",
                "Source": "Table 2",
                "Adjustment Factors": "Age at diagnosis, sex, marital status, ethnicity, education level, occupation, transmission route, year of HIV infection diagnosis"
            },
            "measures": "[Unadjusted Coefficient, Unadjusted 95% CI, Unadjusted P, Adjusted Coefficient, Adjusted 95% CI, Adjusted P]",
            "outcomes": "[87, (46\u2013128), <0.001, 72, (37\u2013107), <0.001]"
        }
    ],
    "PMC7414801_2": [
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "HIV detection visit",
                "measure": "HIV VL",
                "participants": "381",
                "percentage": "100"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[381, 100]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M3",
                "measure": "HIV VL",
                "participants": "114",
                "percentage": "30"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[114, 30]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M6",
                "measure": "HIV VL",
                "participants": "73",
                "percentage": "19"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[73, 19]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M9",
                "measure": "HIV VL",
                "participants": "43",
                "percentage": "11"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[43, 11]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M12",
                "measure": "HIV VL",
                "participants": "26",
                "percentage": "7"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[26, 7]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M15",
                "measure": "HIV VL",
                "participants": "17",
                "percentage": "4"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[17, 4]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "HIV detection visit",
                "measure": "CD4",
                "participants": "382",
                "percentage": "100"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[382, 100]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M3",
                "measure": "CD4",
                "participants": "115",
                "percentage": "30"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[115, 30]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M6",
                "measure": "CD4",
                "participants": "73",
                "percentage": "19"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[73, 19]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M9",
                "measure": "CD4",
                "participants": "44",
                "percentage": "12"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[44, 12]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M12",
                "measure": "CD4",
                "participants": "26",
                "percentage": "7"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[26, 7]"
        },
        {
            "subject": {
                "analysis_group": "as-randomized",
                "total_participants": "382",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M15",
                "measure": "CD4",
                "participants": "17",
                "percentage": "4"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[17, 4]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "HIV detection visit",
                "measure": "HIV VL",
                "participants": "330",
                "percentage": "100"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[330, 100]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M3",
                "measure": "HIV VL",
                "participants": "99",
                "percentage": "30"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[99, 30]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M6",
                "measure": "HIV VL",
                "participants": "65",
                "percentage": "20"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[65, 20]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M9",
                "measure": "HIV VL",
                "participants": "40",
                "percentage": "12"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[40, 12]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M12",
                "measure": "HIV VL",
                "participants": "25",
                "percentage": "8"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[25, 8]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M15",
                "measure": "HIV VL",
                "participants": "14",
                "percentage": "4"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[14, 4]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "HIV detection visit",
                "measure": "CD4",
                "participants": "331",
                "percentage": "100"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[331, 100]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M3",
                "measure": "CD4",
                "participants": "99",
                "percentage": "30"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[99, 30]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M6",
                "measure": "CD4",
                "participants": "64",
                "percentage": "19"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[64, 19]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M9",
                "measure": "CD4",
                "participants": "40",
                "percentage": "12"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[40, 12]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M12",
                "measure": "CD4",
                "participants": "25",
                "percentage": "8"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[25, 8]"
        },
        {
            "subject": {
                "analysis_group": "continuous use",
                "total_participants": "331",
                "excluded_participants": "women infected at baseline and visits following ART initiation",
                "timepoint": "M15",
                "measure": "CD4",
                "participants": "14",
                "percentage": "4"
            },
            "measures": "[participants, percentage]",
            "outcomes": "[14, 4]"
        }
    ],
    "PMC9624454_2": [
        {
            "subject": {
                "HIV Exposure": "All children",
                "No.": "1024",
                "CMV Viremia": "314 (30.7)",
                "CMV Viremia \u2264 1000 IU/mL": "59 (5.8)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[314 (30.7), 59 (5.8), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV unexposed",
                "No.": "872",
                "CMV Viremia": "253 (29.0)",
                "CMV Viremia \u2264 1000 IU/mL": "45 (5.2)",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.3 (1.9\u20132.7)"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[253 (29.0), 45 (5.2), 2.3 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV exposed",
                "No.": "118",
                "CMV Viremia": "45 (38.1)",
                "P Value (CMV Viremia)": ".061",
                "CMV Viremia \u2264 1000 IU/mL": "10 (8.5)",
                "P Value (CMV Viremia \u2264 1000 IU/mL)": ".18",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (2.0\u20132.9)",
                "P Value (log10 CMV IU/mL in Viremics)": ".24",
                "Footnote a": "HIV-exposed or infected group includes 6 children who were HIV exposed but whose HIV infection status was unknown",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[45 (38.1), 10 (8.5), 2.4 (2.0\u20132.9)]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV exposed uninfected",
                "No.": "97",
                "CMV Viremia": "36 (37.1)",
                "P Value (CMV Viremia)": ".088",
                "CMV Viremia \u2264 1000 IU/mL": "6 (6.2)",
                "P Value (CMV Viremia \u2264 1000 IU/mL)": ".56",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 2.4 (1.9\u20132.7)",
                "P Value (log10 CMV IU/mL in Viremics)": ".74",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[36 (37.1), 6 (6.2), 2.4 (1.9\u20132.7)]"
        },
        {
            "subject": {
                "HIV Exposure": "HIV infected",
                "No.": "15",
                "CMV Viremia": "6 (40.0)",
                "P Value (CMV Viremia)": ".39",
                "CMV Viremia \u2264 1000 IU/mL": "3 (20.0)",
                "P Value (CMV Viremia \u2264 1000 IU/mL)": ".015",
                "log10 CMV IU/mL in Viremics": "Median (IQR), 3.2 (2.6\u20135.3)",
                "P Value (log10 CMV IU/mL in Viremics)": ".012",
                "Footnote b": "Comparison to CMV detection in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote c": "Comparison to CMV detection \u2264 1000 IU/mL in HIV-unexposed children, \u03c7\u00b2 test",
                "Footnote d": "Comparison of CMV viral load distribution to HIV-unexposed children, Wilcoxon rank-sum test"
            },
            "measures": "[CMV Viremia, CMV Viremia \u2264 1000 IU/mL, log10 CMV IU/mL in Viremics]",
            "outcomes": "[6 (40.0), 3 (20.0), 3.2 (2.6\u20135.3)]"
        }
    ],
    "PMC4549947_4": [
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "females",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[1.3]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "males",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[3.5, p = 0.008]",
            "outcomes": "[1.5\u20135.5]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "unspecified",
                "race/ethnicity": "Hispanics",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[2.6]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "unspecified",
                "race/ethnicity": "African American",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[3.1, p = 0.01]",
            "outcomes": "[2.3\u20133.5]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "unspecified",
                "race/ethnicity": "unspecified",
                "alcohol use": "yes",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[2.6]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "females",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.35]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "males",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.35]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "unspecified",
                "race/ethnicity": "Hispanics",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.05]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "executive function",
                "gender": "unspecified",
                "race/ethnicity": "African American",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.05]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "females",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[0.9]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "males",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[1.8, p = 0.01]",
            "outcomes": "[1.2\u20132.9]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "Hispanics",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[1.9]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "African American",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[1.5]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "unspecified",
                "alcohol use": "yes",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[1.6, p = 0.03]",
            "outcomes": "[1.4\u20132.4]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "females",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.013]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "males",
                "race/ethnicity": "unspecified",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.013]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "Hispanics",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.72]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "African American",
                "alcohol use": "unspecified",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.72]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "gene": "DRD2",
                "SNP": "rs6277",
                "trait": "cognitive flexibility",
                "gender": "unspecified",
                "race/ethnicity": "unspecified",
                "alcohol use": "yes",
                "Hardy\u2013Weinberg equilibrium": "true"
            },
            "measures": "[p_interaction = 0.32]",
            "outcomes": "[]"
        }
    ],
    "PMC6694514_3": [
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "12",
                "Percentage of total G3+ events in HIV group": "30.0%"
            },
            "measures": "[Event count]",
            "outcomes": "[12]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "15",
                "Percentage of total G3+ events in HIV group": "25.0%"
            },
            "measures": "[Event count]",
            "outcomes": "[15]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Respiratory and thoracic disorders",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "7",
                "Percentage of total G3+ events in HIV group": "17.5%"
            },
            "measures": "[Event count]",
            "outcomes": "[7]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Respiratory and thoracic disorders",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "13",
                "Percentage of total G3+ events in HIV group": "21.7%"
            },
            "measures": "[Event count]",
            "outcomes": "[13]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Blood and lymphatic disorders",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "6",
                "Percentage of total G3+ events in HIV group": "15.0%"
            },
            "measures": "[Event count]",
            "outcomes": "[6]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Blood and lymphatic disorders",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "10",
                "Percentage of total G3+ events in HIV group": "16.7%"
            },
            "measures": "[Event count]",
            "outcomes": "[10]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Infections and infestations",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "3",
                "Percentage of total G3+ events in HIV group": "7.5%"
            },
            "measures": "[Event count]",
            "outcomes": "[3]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Infections and infestations",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "5",
                "Percentage of total G3+ events in HIV group": "8.3%"
            },
            "measures": "[Event count]",
            "outcomes": "[5]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Metabolism and nutrition disorders",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "3",
                "Percentage of total G3+ events in HIV group": "7.5%"
            },
            "measures": "[Event count]",
            "outcomes": "[3]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Metabolism and nutrition disorders",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "4",
                "Percentage of total G3+ events in HIV group": "6.7%"
            },
            "measures": "[Event count]",
            "outcomes": "[4]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Other",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "9",
                "Percentage of total G3+ events in HIV group": "17.5%"
            },
            "measures": "[Event count]",
            "outcomes": "[9]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Other",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Event count": "13",
                "Percentage of total G3+ events in HIV group": "16.7%"
            },
            "measures": "[Event count]",
            "outcomes": "[13]"
        },
        {
            "subject": {
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients experiencing \u22651 AE": "20",
                "Percentage of patients experiencing \u22651 AE": "47.6%"
            },
            "measures": "[Patients experiencing \u22651 AE]",
            "outcomes": "[20]"
        },
        {
            "subject": {
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients experiencing \u22651 AE": "34",
                "Percentage of patients experiencing \u22651 AE": "15.5%"
            },
            "measures": "[Patients experiencing \u22651 AE]",
            "outcomes": "[34]"
        },
        {
            "subject": {
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients with treatment-related AE": "11",
                "Percentage of patients with treatment-related AE": "26.2%"
            },
            "measures": "[Patients with treatment-related AE]",
            "outcomes": "[11]"
        },
        {
            "subject": {
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients with treatment-related AE": "14",
                "Percentage of patients with treatment-related AE": "6.4%"
            },
            "measures": "[Patients with treatment-related AE]",
            "outcomes": "[14]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-positive",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients experiencing events": "6",
                "Percentage of patients experiencing events": "14.3%"
            },
            "measures": "[Patients experiencing events]",
            "outcomes": "[6]"
        },
        {
            "subject": {
                "Adverse Event SOC": "Hepatobiliary disorders",
                "HIV status": "HIV-negative",
                "Trial": "REMoxTB",
                "Population": "Matched",
                "Event severity": "Grade 3 or 4",
                "Patients experiencing events": "9",
                "Percentage of patients experiencing events": "4.1%"
            },
            "measures": "[Patients experiencing events]",
            "outcomes": "[9]"
        }
    ],
    "PMC6937831_2": [
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "cause": "Cancer",
                "number_of_deaths": "6",
                "percentage": "4%",
                "definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[6, 4%]"
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "cause": "Other diseases",
                "number_of_deaths": "10",
                "percentage": "8%",
                "definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[10, 8%]"
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "cause": "CVD",
                "number_of_deaths": "12",
                "percentage": "9%"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[12, 9%]"
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "cause": "Hepatic/liver-related",
                "number_of_deaths": "34",
                "percentage": "24%"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[34, 24%]"
        },
        {
            "subject": {
                "death_category": "Non-AIDS-Related Death (NARD)",
                "cause": "External death",
                "number_of_deaths": "78",
                "percentage": "55%",
                "definition": "Sudden death, including accident, overdose, and suicide"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[78, 55%]"
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "cause": "Other diseases",
                "number_of_deaths": "2",
                "percentage": "1%",
                "definition": "Unknown death categorized based on CD4 count within 6-months prior to the date of death. The CD4 cell count of lower than 200 cells/mm\u00b2 was categorized as ARM and otherwise as NARM"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[2, 1%]"
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "cause": "Cancer",
                "number_of_deaths": "8",
                "percentage": "3%",
                "definition": "Based on the CoDe protocol, AIDS-related cancers like cervical cancer were considered as ARM and other causes unrelated to HIV like lung cancer were categorized as NARD"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[8, 3%]"
        },
        {
            "subject": {
                "death_category": "AIDS-Related Death (ARD)",
                "cause": "Opportunistic",
                "number_of_deaths": "241",
                "percentage": "96%"
            },
            "measures": "[number_of_deaths, percentage]",
            "outcomes": "[241, 96%]"
        },
        {
            "subject": {
                "total_deaths": "14",
                "percentage": "7%",
                "cause": "Cancer",
                "context": "Mentioned in paragraph as related to Table 2"
            },
            "measures": "[total_deaths, percentage]",
            "outcomes": "[14, 7%]"
        }
    ],
    "PMC8340029_2": [
        {
            "subject": {
                "context": "Including study visits with on-site PrEP access",
                "time period": "Before access",
                "number of infections/person-years": "133/2860",
                "incidence": "4\u00b765%",
                "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            }
        },
        {
            "subject": {
                "context": "Including study visits with on-site PrEP access",
                "time period": "After access",
                "number of infections/person-years": "12/556",
                "incidence": "2\u00b716%",
                "adjusted incidence rate ratio (95% CI)": "0\u00b745 (0\u00b725-0\u00b782)",
                "p value": "0\u00b70085",
                "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0\u00b745 (0\u00b725-0\u00b781), 0\u00b70076]"
        },
        {
            "subject": {
                "context": "180 days before versus 180 days after on-site PrEP access",
                "time period": "Before access",
                "number of infections/person-years": "46/919",
                "incidence": "5\u00b700%",
                "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            }
        },
        {
            "subject": {
                "context": "180 days before versus 180 days after on-site PrEP access",
                "time period": "After access",
                "number of infections/person-years": "11/481",
                "incidence": "2\u00b729%",
                "adjusted incidence rate ratio (95% CI)": "0\u00b743 (0\u00b722-0\u00b783)",
                "p value": "0\u00b7012",
                "adjustment factors": "Adjusted for study site, randomisation arm, age <24 years, woman reporting her partner had other partners (baseline and follow-up), any unprotected sex (baseline and follow-up), and any new partner (follow-up only)"
            },
            "measures": "[adjusted incidence rate ratio (95% CI), p value]",
            "outcomes": "[0\u00b744 (0\u00b723-0\u00b785), 0\u00b7015]"
        }
    ],
    "PMC8391097_3": [
        {
            "subject": {
                "PrEP status": "Overall",
                "HIV infections": "No./total No. of individuals, 91/13 861",
                "Total follow-up": "person-years, 26 210",
                "Incidence (95% CI)": "per 100 person-years, 0.35 (0.28-0.43)",
                "Exclusion criteria": "Excludes individuals who were diagnosed with HIV during the eligibility assessment at PrEP linkage"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.35]"
        },
        {
            "subject": {
                "PrEP status": "Linked but not prescribed PrEP",
                "HIV infections": "No./total No. of individuals, 36/3013",
                "Total follow-up": "person-years, 4119",
                "Incidence (95% CI)": "per 100 person-years, 0.87 (0.63-1.21)"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.87]"
        },
        {
            "subject": {
                "PrEP status": "Prescribed PrEP but did not initiate",
                "HIV infections": "No./total No. of individuals, 13/811",
                "Total follow-up": "person-years, 1226",
                "Incidence (95% CI)": "per 100 person-years, 1.06 (0.62-1.83)"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[1.06]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued but reinitiated PrEP",
                "HIV infections": "No./total No. of individuals, 4/1082",
                "Total follow-up": "person-years, 1420",
                "Incidence (95% CI)": "per 100 person-years, 0.28 (0.11-0.75)"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.28]"
        },
        {
            "subject": {
                "PrEP status": "Discontinued and did not reinitiate PrEP",
                "HIV infections": "No./total No. of individuals, 38/2108",
                "Total follow-up": "person-years, 2973",
                "Incidence (95% CI)": "per 100 person-years, 1.28 (0.93-1.76)"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[1.28]"
        },
        {
            "subject": {
                "PrEP status": "Persistent on PrEP",
                "HIV infections": "No./total No. of individuals, 0/5367",
                "Total follow-up": "person-years, 9139",
                "Incidence (95% CI)": "per 100 person-years, 0.00 (0.00-0.04)",
                "Definition": "Persistent on PrEP refers to individuals who initiated and remained on PrEP throughout follow-up",
                "CI type": "One-sided 97.5% upper CI"
            },
            "measures": "[Incidence rate]",
            "outcomes": "[0.00]"
        }
    ],
    "PMC8748440_2": [
        {
            "subject": {
                "gene": "ISG15",
                "HR": "0.29 (0.11\u20130.81)",
                "p value": "0.0091",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.29 (0.11\u20130.81), 0.0091]"
        },
        {
            "subject": {
                "gene": "IFI6",
                "HR": "0.18 (0.037\u20130.86)",
                "p value": "0.014",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.18 (0.037\u20130.86), 0.014]"
        },
        {
            "subject": {
                "gene": "IFI44L",
                "HR": "0.55 (0.27\u20131.1)",
                "p value": "0.083",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.55 (0.27\u20131.1), 0.083]"
        },
        {
            "subject": {
                "gene": "IFI44",
                "HR": "0.23 (0.047\u20131.2)",
                "p value": "0.045",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23 (0.047\u20131.2), 0.045]"
        },
        {
            "subject": {
                "gene": "IFIT1",
                "HR": "0.37 (0.12\u20131.1)",
                "p value": "0.054",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.37 (0.12\u20131.1), 0.054]"
        },
        {
            "subject": {
                "gene": "OAS3",
                "HR": "0.52 (0.22\u20131.3)",
                "p value": "0.15",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.52 (0.22\u20131.3), 0.15]"
        },
        {
            "subject": {
                "gene": "XAF1",
                "HR": "0.3 (0.1\u20130.92)",
                "p value": "0.027",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.3 (0.1\u20130.92), 0.027]"
        },
        {
            "subject": {
                "gene": "TRIM25",
                "HR": "0.074 (0.0068\u20130.8)",
                "p value": "0.023",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.074 (0.0068\u20130.8), 0.023]"
        },
        {
            "subject": {
                "gene": "CMPK2",
                "HR": "0.23 (0.037\u20131.5)",
                "p value": "0.074",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23 (0.037\u20131.5), 0.074]"
        },
        {
            "subject": {
                "gene": "RSAD2",
                "HR": "0.2 (0.041\u20130.99)",
                "p value": "0.032",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.2 (0.041\u20130.99), 0.032]"
        },
        {
            "subject": {
                "gene": "EIF2AK2",
                "HR": "0.54 (0.12\u20132.4)",
                "p value": "0.42",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.54 (0.12\u20132.4), 0.42]"
        },
        {
            "subject": {
                "gene": "USP18",
                "HR": "0.23 (0.062\u20130.84)",
                "p value": "0.022",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.23 (0.062\u20130.84), 0.022]"
        },
        {
            "subject": {
                "gene": "HERC6",
                "HR": "0.16 (0.019\u20131.3)",
                "p value": "0.057",
                "analysis type": "Univariable Cox regression",
                "module": "salmon Module 1",
                "identified by": "WGCNA"
            },
            "measures": "[HR, p value]",
            "outcomes": "[0.16 (0.019\u20131.3), 0.057]"
        }
    ],
    "PMC7615197_2": [
        {
            "subject": {
                "population": "intention-to-treat",
                "treatment": "dexamethasone",
                "control": "placebo",
                "deaths_dexamethasone": "116/263",
                "deaths_placebo": "126/257",
                "hazard_ratio": "0.85",
                "confidence_interval": "(0.66, 1.10)",
                "p_value": "0.22",
                "test_for_proportional_hazards": "0.36",
                "heterogeneity_p_value": "not reported",
                "primary_endpoint": "death from any cause over the first 12 months after randomization",
                "analysis_method": "Cox proportional hazards regression model",
                "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                "time_transformation": "Kaplan-Meier",
                "covariates": "treatment only"
            },
            "measures": "[hazard_ratio, confidence_interval, p_value]",
            "outcomes": "[0.85, (0.66, 1.10), 0.22]"
        },
        {
            "subject": {
                "population": "modified MRC grade",
                "subgroup": "Grade I",
                "treatment": "dexamethasone",
                "control": "placebo",
                "deaths_dexamethasone": "22/99",
                "deaths_placebo": "28/97",
                "hazard_ratio": "0.72",
                "confidence_interval": "(0.41, 1.25)",
                "p_value": "0.24",
                "test_for_proportional_hazards": "0.15",
                "heterogeneity_p_value": "0.63",
                "primary_endpoint": "death from any cause over the first 12 months after randomization",
                "analysis_method": "Cox proportional hazards regression model",
                "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                "time_transformation": "Kaplan-Meier",
                "covariates": "TBM MRC severity grade at enrolment"
            },
            "measures": "[hazard_ratio, confidence_interval, p_value]",
            "outcomes": "[0.72, (0.41, 1.25), 0.24]"
        },
        {
            "subject": {
                "population": "modified MRC grade",
                "subgroup": "Grade II",
                "treatment": "dexamethasone",
                "control": "placebo",
                "deaths_dexamethasone": "60/125",
                "deaths_placebo": "68/126",
                "hazard_ratio": "0.82",
                "confidence_interval": "(0.58, 1.16)",
                "p_value": "0.27",
                "test_for_proportional_hazards": "0.57",
                "heterogeneity_p_value": "0.63",
                "primary_endpoint": "death from any cause over the first 12 months after randomization",
                "analysis_method": "Cox proportional hazards regression model",
                "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                "time_transformation": "Kaplan-Meier",
                "covariates": "TBM MRC severity grade at enrolment"
            },
            "measures": "[hazard_ratio, confidence_interval, p_value]",
            "outcomes": "[0.82, (0.58, 1.16), 0.27]"
        },
        {
            "subject": {
                "population": "modified MRC grade",
                "subgroup": "Grade III",
                "treatment": "dexamethasone",
                "control": "placebo",
                "deaths_dexamethasone": "34/39",
                "deaths_placebo": "30/34",
                "hazard_ratio": "1.11",
                "confidence_interval": "(0.70, 1.77)",
                "p_value": "0.65",
                "test_for_proportional_hazards": "0.89",
                "heterogeneity_p_value": "0.63",
                "primary_endpoint": "death from any cause over the first 12 months after randomization",
                "analysis_method": "Cox proportional hazards regression model",
                "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                "time_transformation": "Kaplan-Meier",
                "covariates": "TBM MRC severity grade at enrolment"
            },
            "measures": "[hazard_ratio, confidence_interval, p_value]",
            "outcomes": "[1.11, (0.70, 1.77), 0.65]"
        },
        {
            "subject": {
                "population": "intention-to-treat",
                "analysis_method": "Cox proportional hazards regression model",
                "effect_measure": "hazard ratio comparing dexamethasone vs. placebo",
                "time_transformation": "Kaplan-Meier",
                "covariates": "treatment only",
                "heterogeneity_of_effect": "not observed",
                "subgroup_analysis": "pre-specified sub-groups",
                "primary_endpoint": "death from any cause over the first 12 months after randomization",
                "heterogeneity_test_method": "likelihood ratio test",
                "interaction_model": "treatment effect and subgroup",
                "subgroup_covariates": "TBM MRC severity grade at enrolment"
            },
            "measures": "[]",
            "outcomes": ""
        }
    ],
    "PMC9008168_2": [
        {
            "subject": {
                "study_population": "participants at risk",
                "total_population": "2144",
                "developed_BMI_\u226525_kg/m\u00b2": "516",
                "table_reference": "Table 2",
                "incidence_rate_comparison": "similar among participants without HIV and those on ART",
                "highest_incidence_group": "participants on non-TLD ART"
            },
            "measures": "[]",
            "outcomes": "[]"
        },
        {
            "subject": {
                "group": "Participants without HIV",
                "incidence_rate_cases_per_1000_PY": "69.8",
                "incidence_rate_95%_CI": "54.7\u201389.0",
                "HR": "1.00",
                "HR_reference": "Reference"
            },
            "measures": "[incidence_rate_cases_per_1000_PY, HR]",
            "outcomes": "[69.8, 1.00]"
        },
        {
            "subject": {
                "group": "PLWH on non-TLD ART",
                "incidence_rate_cases_per_1000_PY": "77.1",
                "incidence_rate_95%_CI": "69.8\u201385.2",
                "HR": "1.13",
                "HR_95%_CI": "0.79\u20131.63"
            },
            "measures": "[incidence_rate_cases_per_1000_PY, HR]",
            "outcomes": "[77.1, 1.13]"
        },
        {
            "subject": {
                "group": "PLWH on TLD",
                "incidence_rate_cases_per_1000_PY": "73.3",
                "incidence_rate_95%_CI": "54.0\u201399.6",
                "HR": "1.77",
                "HR_95%_CI": "1.22\u20132.55"
            },
            "measures": "[incidence_rate_cases_per_1000_PY, HR]",
            "outcomes": "[73.3, 1.77]"
        },
        {
            "subject": {
                "group": "PLWH, ART na\u00efve",
                "incidence_rate_cases_per_1000_PY": "37.7",
                "incidence_rate_95%_CI": "24.1\u201359.1",
                "HR": "0.43",
                "HR_95%_CI": "0.27\u20130.70"
            },
            "measures": "[incidence_rate_cases_per_1000_PY, HR]",
            "outcomes": "[37.7, 0.43]"
        },
        {
            "subject": {
                "abbreviation_PLWH": "people living with HIV",
                "abbreviation_TLD": "tenofovir/lamivudine/dolutegravir",
                "abbreviation_PY": "person-years"
            },
            "measures": "[]",
            "outcomes": "[]"
        }
    ],
    "PMC7644038_3": [
        {
            "subject": {
                "condition": "Depression",
                "population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "comparison group": "No HIV",
                "comparison group prevalence": "6.2%",
                "HIV group prevalence": "24.3%",
                "percent difference": "291.9%",
                "significance level": "***",
                "logistic regression model": "Coefficients from logistic regression model",
                "odds ratio": "2.29",
                "confidence interval": "[2.22, 2.35]",
                "year": "2016",
                "upper age limit": "98 years",
                "statistical test": "chi-squared test",
                "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                "omitted group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                "weighting": "probability weights to reflect differential selection probabilities based on HIV diagnosis",
                "Bonferroni correction": "applied",
                "number of tests": "11"
            },
            "measures": "[2.22, 2.35]",
            "outcomes": [
                "[24.3%, 6.2%, 291.9%, 2.29]",
                "[HIV group prevalence, comparison group prevalence, percent difference, odds ratio]"
            ]
        },
        {
            "subject": {
                "condition": "Chronic kidney disease",
                "population": "Medicare beneficiaries at age 65 between 2011\u20132016",
                "comparison group": "No HIV",
                "comparison group prevalence": "18.9%",
                "HIV group prevalence": "46.2%",
                "percent difference": "144.4%",
                "significance level": "***",
                "logistic regression model": "Coefficients from logistic regression model",
                "odds ratio": "1.92",
                "confidence interval": "[1.88, 1.97]",
                "year": "2016",
                "upper age limit": "98 years",
                "statistical test": "chi-squared test",
                "controls": "age, race/ethnicity, sex, state, rural/urban residence, dual enrollment in Medicaid",
                "omitted group": "White, urban, non-Medicaid enrolled males between the age of 65 and 74",
                "weighting": "probability weights to reflect differential selection probabilities based on HIV diagnosis",
                "Bonferroni correction": "applied",
                "number of tests": "11"
            },
            "measures": "[1.88, 1.97]",
            "outcomes": [
                "[46.2%, 18.9%, 144.4%, 1.92]",
                "[HIV group prevalence, comparison group prevalence, percent difference, odds ratio]"
            ]
        }
    ],
    "PMC6033411_2": [
        {
            "subject": {
                "Characteristic": "Age (years)",
                "Age group": "15 and younger",
                "Total number": "69 (34.5%)",
                "Clustered": "22 (37.3%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "Age (years)",
                "Age group": "16",
                "Total number": "46 (23%)",
                "Clustered": "13 (22%)",
                "Odds ratio": "0.84 (0.36\u20131.89)",
                "P-value": "0.67"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.84 (0.36\u20131.89), 0.67]"
        },
        {
            "subject": {
                "Characteristic": "Age (years)",
                "Age group": "17+",
                "Total number": "85 (42.5%)",
                "Clustered": "24 (40.7%)",
                "Odds ratio": "0.87 (0.43\u20131.76)",
                "P-value": "0.69"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.87 (0.43\u20131.76), 0.69]"
        },
        {
            "subject": {
                "Characteristic": "School grade",
                "Grade group": "8\u20139",
                "Total number": "90 (45%)",
                "Clustered": "30 (50.8%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "School grade",
                "Grade group": "10\u201312",
                "Total number": "110 (55%)",
                "Clustered": "29 (49.2%)",
                "Odds ratio": "0.8 (0.43\u20131.52)",
                "P-value": "0.5"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.8 (0.43\u20131.52), 0.5]"
        },
        {
            "subject": {
                "Characteristic": "Household income (R)",
                "Income group": "<999",
                "Total number": "61 (30.5%)",
                "Clustered": "22 (37.3%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "Household income (R)",
                "Income group": "10,000\u201399,000",
                "Total number": "112 (56%)",
                "Clustered": "27 (45.8%)",
                "Odds ratio": "0.56 (0.29\u20131.11)",
                "P-value": "0.1"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.56 (0.29\u20131.11), 0.1]"
        },
        {
            "subject": {
                "Characteristic": "Household income (R)",
                "Income group": ">100,000",
                "Total number": "27 (12.5%)",
                "Clustered": "10 (16.9%)",
                "Odds ratio": "1.04 (0.39\u20132.65)",
                "P-value": "0.93"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[1.04 (0.39\u20132.65), 0.93]"
        },
        {
            "subject": {
                "Characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": ">500",
                "Total number": "92 (46%)",
                "Clustered": "30 (50.9%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": "\u2264500",
                "Total number": "75 (37.5%)",
                "Clustered": "19 (32.2%)",
                "Odds ratio": "0.70 (0.35\u20131.37)",
                "P-value": "0.31"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.70 (0.35\u20131.37), 0.31]"
        },
        {
            "subject": {
                "Characteristic": "CD4 cell count, cells/mm\u00b3",
                "CD4 group": "\u2264250",
                "Total number": "15 (7.5%)",
                "Clustered": "4 (6.8%)",
                "Odds ratio": "0.75 (0.2\u20132.4)",
                "P-value": "0.65"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.75 (0.2\u20132.4), 0.65]"
        },
        {
            "subject": {
                "Characteristic": "Major drug resistance mutation",
                "Mutation status": "No",
                "Total number": "180 (90%)",
                "Clustered": "55 (93.2)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "Major drug resistance mutation",
                "Mutation status": "Yes",
                "Total number": "20 (10%)",
                "Clustered": "4 (6.8%)",
                "Odds ratio": "0.57 (0.16\u20131.63)",
                "P-value": "0.33"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[0.57 (0.16\u20131.63), 0.33]"
        },
        {
            "subject": {
                "Characteristic": "HSV-2 infection",
                "HSV-2 status": "No",
                "Total number": "90 (45%)",
                "Clustered": "25 (42.4%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "HSV-2 infection",
                "HSV-2 status": "Yes",
                "Total number": "69 (34.5%)",
                "Clustered": "23 (39%)",
                "Odds ratio": "1.3 (0.65\u20132.57)",
                "P-value": "0.45"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[1.3 (0.65\u20132.57), 0.45]"
        },
        {
            "subject": {
                "Characteristic": "Ever pregnant",
                "Pregnancy history": "No",
                "Total number": "122 (61%)",
                "Clustered": "37 (62.7%)",
                "Odds ratio": "1.0 (ref)",
                "P-value": "\u2026"
            },
            "measures": "[Odds ratio]",
            "outcomes": "[1.0 (ref)]"
        },
        {
            "subject": {
                "Characteristic": "Ever pregnant",
                "Pregnancy history": "Yes",
                "Total number": "49 (24.5%)",
                "Clustered": "15 (25.4%)",
                "Odds ratio": "1.01 (0.48\u20132.06)",
                "P-value": "0.971"
            },
            "measures": "[Odds ratio, P-value]",
            "outcomes": "[1.01 (0.48\u20132.06), 0.971]"
        },
        {
            "subject": {
                "Study participants": "200 HIV-infected individuals",
                "Genetic distance threshold": "4.5%",
                "Footnote a": "CD4 cell count data was not available for 18 women",
                "Footnote b": "HSV-2 infection status was not available for 41 women",
                "Footnote c": "Pregnancy history was not available for 29 women",
                "Abbreviation N": "number",
                "Abbreviation CI": "confidence intervals",
                "Abbreviation ref": "reference"
            }
        }
    ]
}